Literature DB >> 16010526

Renal cell carcinoma as a second malignant neoplasm in a patient with non-syndromic hemihypertrophy and previous Wilms tumor.

Greg Kraushaar1, Sheldon Wiebe.   

Abstract

Survivors of childhood Wilms tumors are at an increased risk of second malignant neoplasms. Recently, it has been postulated that renal cell carcinoma is among the malignancies for which this population is at risk. We present the unique case of an adult Wilms tumor survivor with non-syndromic hemihypertrophy (NSHH) who developed renal cell carcinoma. This case highlights the need for close follow-up in two populations: adults who have survived Wilms tumor and those with NSHH.

Entities:  

Mesh:

Year:  2005        PMID: 16010526     DOI: 10.1007/s00247-005-1540-5

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  15 in total

1.  Incidence of malignant tumors in U. S. children.

Authors:  J L Young; R W Miller
Journal:  J Pediatr       Date:  1975-02       Impact factor: 4.406

Review 2.  Hemihypertrophy. Concepts and controversies.

Authors:  R T Ballock; G L Wiesner; M T Myers; G H Thompson
Journal:  J Bone Joint Surg Am       Date:  1997-11       Impact factor: 5.284

Review 3.  Congenital hemihypertrophy with adrenal adenoma and medullary sponge kidney.

Authors:  Y Tomooka; H Onitsuka; T Goya; Y Hayashida; T Kuroiwa; S Kudo; S Miyazaki; M Torisu
Journal:  Br J Radiol       Date:  1988-09       Impact factor: 3.039

4.  Musculoskeletal deformities following treatment of Wilms' tumour.

Authors:  J H Oliver; G Gluck; R B Gledhill; L Chevalier
Journal:  Can Med Assoc J       Date:  1978-09-09       Impact factor: 8.262

5.  Renal neoplasms in adult survivors of childhood Wilms tumor.

Authors:  E E Cherullo; J H Ross; R Kay; A C Novick
Journal:  J Urol       Date:  2001-06       Impact factor: 7.450

6.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

7.  Hemihypertrophy as possible sign of renal cell carcinoma.

Authors:  L Parker; J Kollin; D Vicario; T Nguyen
Journal:  Urology       Date:  1992-09       Impact factor: 2.649

8.  Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential.

Authors:  C Sotelo-Avila; F Gonzalez-Crussi; J W Fowler
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

Review 9.  Screening for Wilms tumor in high-risk individuals.

Authors:  C L Clericuzio; C Johnson
Journal:  Hematol Oncol Clin North Am       Date:  1995-12       Impact factor: 3.722

10.  The epidemiology of renal cell carcinoma. A second look.

Authors:  J E Muscat; D Hoffmann; E L Wynder
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

View more
  4 in total

1.  CT and MRI appearances and radiologic staging of pediatric renal cell carcinoma.

Authors:  Ryan T Downey; Jonathan R Dillman; Maria F Ladino-Torres; Jonathan B McHugh; Peter F Ehrlich; Peter J Strouse
Journal:  Pediatr Radiol       Date:  2012-01-17

2.  Secondary malignant neoplasms after Wilms tumor: an international collaborative study.

Authors:  Norman E Breslow; Jane M Lange; Debra L Friedman; Daniel M Green; Mike M Hawkins; Michael F G Murphy; Joseph P Neglia; Jørgen H Olsen; Susan M Peterson; Charles A Stiller; Leslie L Robison
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

Review 3.  Innovations in the management of Wilms' tumor.

Authors:  Joseph M Gleason; Armando J Lorenzo; Paul R Bowlin; Martin A Koyle
Journal:  Ther Adv Urol       Date:  2014-08

4.  Secondary renal neoplasia following chemotherapy or radiation in pediatric patients.

Authors:  Sounak Gupta; Chad M Vanderbilt; Bradley C Leibovich; Loren Herrera-Hernandez; Aditya Raghunathan; William R Sukov; Jesse S Voss; Emily G Barr Fritcher; Katelyn A Reed; Christine M Lohse; Victor E Reuter; Rafael E Jimenez; R Houston Thompson; John C Cheville
Journal:  Hum Pathol       Date:  2020-07-15       Impact factor: 3.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.